369 related articles for article (PubMed ID: 18331619)
1. Increased mechanosensitivity and nuclear stiffness in Hutchinson-Gilford progeria cells: effects of farnesyltransferase inhibitors.
Verstraeten VL; Ji JY; Cummings KS; Lee RT; Lammerding J
Aging Cell; 2008 Jun; 7(3):383-93. PubMed ID: 18331619
[TBL] [Abstract][Full Text] [Related]
2. Identification of mitochondrial dysfunction in Hutchinson-Gilford progeria syndrome through use of stable isotope labeling with amino acids in cell culture.
Rivera-Torres J; Acín-Perez R; Cabezas-Sánchez P; Osorio FG; Gonzalez-Gómez C; Megias D; Cámara C; López-Otín C; Enríquez JA; Luque-García JL; Andrés V
J Proteomics; 2013 Oct; 91():466-77. PubMed ID: 23969228
[TBL] [Abstract][Full Text] [Related]
3. Incomplete processing of mutant lamin A in Hutchinson-Gilford progeria leads to nuclear abnormalities, which are reversed by farnesyltransferase inhibition.
Glynn MW; Glover TW
Hum Mol Genet; 2005 Oct; 14(20):2959-69. PubMed ID: 16126733
[TBL] [Abstract][Full Text] [Related]
4. Hutchinson-Gilford progeria mutant lamin A primarily targets human vascular cells as detected by an anti-Lamin A G608G antibody.
McClintock D; Gordon LB; Djabali K
Proc Natl Acad Sci U S A; 2006 Feb; 103(7):2154-9. PubMed ID: 16461887
[TBL] [Abstract][Full Text] [Related]
5. Blocking protein farnesylation improves nuclear shape abnormalities in keratinocytes of mice expressing the prelamin A variant in Hutchinson-Gilford progeria syndrome.
Wang Y; Ostlund C; Worman HJ
Nucleus; 2010; 1(5):432-9. PubMed ID: 21326826
[TBL] [Abstract][Full Text] [Related]
6. Farnesyltransferase inhibitor treatment restores chromosome territory positions and active chromosome dynamics in Hutchinson-Gilford progeria syndrome cells.
Mehta IS; Eskiw CH; Arican HD; Kill IR; Bridger JM
Genome Biol; 2011 Aug; 12(8):R74. PubMed ID: 21838864
[TBL] [Abstract][Full Text] [Related]
7. Blocking protein farnesyltransferase improves nuclear blebbing in mouse fibroblasts with a targeted Hutchinson-Gilford progeria syndrome mutation.
Yang SH; Bergo MO; Toth JI; Qiao X; Hu Y; Sandoval S; Meta M; Bendale P; Gelb MH; Young SG; Fong LG
Proc Natl Acad Sci U S A; 2005 Jul; 102(29):10291-6. PubMed ID: 16014412
[TBL] [Abstract][Full Text] [Related]
8. Dermal fibroblasts in Hutchinson-Gilford progeria syndrome with the lamin A G608G mutation have dysmorphic nuclei and are hypersensitive to heat stress.
Paradisi M; McClintock D; Boguslavsky RL; Pedicelli C; Worman HJ; Djabali K
BMC Cell Biol; 2005 Jun; 6():27. PubMed ID: 15982412
[TBL] [Abstract][Full Text] [Related]
9. Inhibiting farnesylation of progerin prevents the characteristic nuclear blebbing of Hutchinson-Gilford progeria syndrome.
Capell BC; Erdos MR; Madigan JP; Fiordalisi JJ; Varga R; Conneely KN; Gordon LB; Der CJ; Cox AD; Collins FS
Proc Natl Acad Sci U S A; 2005 Sep; 102(36):12879-84. PubMed ID: 16129833
[TBL] [Abstract][Full Text] [Related]
10. Distinct structural and mechanical properties of the nuclear lamina in Hutchinson-Gilford progeria syndrome.
Dahl KN; Scaffidi P; Islam MF; Yodh AG; Wilson KL; Misteli T
Proc Natl Acad Sci U S A; 2006 Jul; 103(27):10271-10276. PubMed ID: 16801550
[TBL] [Abstract][Full Text] [Related]
11. Sulforaphane enhances progerin clearance in Hutchinson-Gilford progeria fibroblasts.
Gabriel D; Roedl D; Gordon LB; Djabali K
Aging Cell; 2015 Feb; 14(1):78-91. PubMed ID: 25510262
[TBL] [Abstract][Full Text] [Related]
12. Farnesyltransferase inhibitor and rapamycin correct aberrant genome organisation and decrease DNA damage respectively, in Hutchinson-Gilford progeria syndrome fibroblasts.
Bikkul MU; Clements CS; Godwin LS; Goldberg MW; Kill IR; Bridger JM
Biogerontology; 2018 Dec; 19(6):579-602. PubMed ID: 29907918
[TBL] [Abstract][Full Text] [Related]
13. Transient introduction of human telomerase mRNA improves hallmarks of progeria cells.
Li Y; Zhou G; Bruno IG; Zhang N; Sho S; Tedone E; Lai TP; Cooke JP; Shay JW
Aging Cell; 2019 Aug; 18(4):e12979. PubMed ID: 31152494
[TBL] [Abstract][Full Text] [Related]
14. Epidermal expression of the truncated prelamin A causing Hutchinson-Gilford progeria syndrome: effects on keratinocytes, hair and skin.
Wang Y; Panteleyev AA; Owens DM; Djabali K; Stewart CL; Worman HJ
Hum Mol Genet; 2008 Aug; 17(15):2357-69. PubMed ID: 18442998
[TBL] [Abstract][Full Text] [Related]
15. Defective lamin A-Rb signaling in Hutchinson-Gilford Progeria Syndrome and reversal by farnesyltransferase inhibition.
Marji J; O'Donoghue SI; McClintock D; Satagopam VP; Schneider R; Ratner D; Worman HJ; Gordon LB; Djabali K
PLoS One; 2010 Jun; 5(6):e11132. PubMed ID: 20559568
[TBL] [Abstract][Full Text] [Related]
16. Blocking protein farnesyltransferase improves nuclear shape in fibroblasts from humans with progeroid syndromes.
Toth JI; Yang SH; Qiao X; Beigneux AP; Gelb MH; Moulson CL; Miner JH; Young SG; Fong LG
Proc Natl Acad Sci U S A; 2005 Sep; 102(36):12873-8. PubMed ID: 16129834
[TBL] [Abstract][Full Text] [Related]
17. Rapamycin reverses cellular phenotypes and enhances mutant protein clearance in Hutchinson-Gilford progeria syndrome cells.
Cao K; Graziotto JJ; Blair CD; Mazzulli JR; Erdos MR; Krainc D; Collins FS
Sci Transl Med; 2011 Jun; 3(89):89ra58. PubMed ID: 21715679
[TBL] [Abstract][Full Text] [Related]
18. LMNA-associated cardiocutaneous progeria: an inherited autosomal dominant premature aging syndrome with late onset.
Kane MS; Lindsay ME; Judge DP; Barrowman J; Ap Rhys C; Simonson L; Dietz HC; Michaelis S
Am J Med Genet A; 2013 Jul; 161A(7):1599-611. PubMed ID: 23666920
[TBL] [Abstract][Full Text] [Related]
19. Progeria, the nucleolus and farnesyltransferase inhibitors.
Mehta IS; Bridger JM; Kill IR
Biochem Soc Trans; 2010 Feb; 38(Pt 1):287-91. PubMed ID: 20074076
[TBL] [Abstract][Full Text] [Related]
20. DNA damage responses in progeroid syndromes arise from defective maturation of prelamin A.
Liu Y; Rusinol A; Sinensky M; Wang Y; Zou Y
J Cell Sci; 2006 Nov; 119(Pt 22):4644-9. PubMed ID: 17062639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
